Rational use of tocilizumab in the treatment of novel coronavirus pneumonia
S Zhang, L Li, A Shen, Y Chen, Z Qi - Clinical drug investigation, 2020 - Springer
Since December 2019, a novel coronavirus pneumonia (COVID-19) has broken out in
Wuhan, China and spread rapidly. Recent studies have found that⁓ 15.7% of patients …
Wuhan, China and spread rapidly. Recent studies have found that⁓ 15.7% of patients …
Treatment with tocilizumab for patients with COVID‐19 infections: a case‐series study
Y Mo, O Adarkwah, J Zeibeq, E Pinelis… - The Journal of …, 2021 - Wiley Online Library
Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin‐6 receptor,
holds the potential for treating coronavirus disease 2019 (COVID‐19) patients, particularly …
holds the potential for treating coronavirus disease 2019 (COVID‐19) patients, particularly …
Efficacy of tocilizumab therapy in different subtypes of COVID-19 cytokine storm syndrome
O Oliynyk, W Barg, A Slifirczyk, Y Oliynyk, V Gurianov… - Viruses, 2021 - mdpi.com
Background: Cytokine storm in COVID-19 is heterogenous. There are at least three
subtypes: cytokine release syndrome (CRS), macrophage activation syndrome (MAS), and …
subtypes: cytokine release syndrome (CRS), macrophage activation syndrome (MAS), and …
A comprehensive review of tocilizumab in COVID‐19 acute respiratory distress syndrome
Currently, the world is facing the pandemic of a novel strain of beta‐coronavirus known as
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Acute respiratory distress …
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Acute respiratory distress …
Why tocilizumab could be an effective treatment for severe COVID-19?
B Fu, X Xu, H Wei - Journal of translational medicine, 2020 - Springer
A severe pneumonia-associated respiratory syndrome caused by a new coronavirus was
identified in December 2019 (COVID-19), spread rapidly and has become a world-wide …
identified in December 2019 (COVID-19), spread rapidly and has become a world-wide …
[HTML][HTML] “Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience”, a retrospective study-original article
Background The first case of Infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) was diagnosed in Wuhan, China in 2019. In the first half of 2020, this disease …
(SARS-CoV-2) was diagnosed in Wuhan, China in 2019. In the first half of 2020, this disease …
[HTML][HTML] Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
Background Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced
cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …
cytokine release syndrome and it may provide clinical benefit for selected COVID–19 …
Tocilizumab: from rheumatic diseases to COVID-19
Tocilizumab is a humanised interleukin-6 receptor-inhibiting monoclonal antibody that is
currently approved for the treatment of rheumatoid arthritis and other immune-related …
currently approved for the treatment of rheumatoid arthritis and other immune-related …
[HTML][HTML] Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
E Huang, S Isonaka, H Yang, E Salce… - International Journal of …, 2021 - Elsevier
Objective Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …
infections, and cytokine storm is associated with disease severity. Tocilizumab, an …
[HTML][HTML] Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis
CW Nugroho, SD Suryantoro, Y Yuliasih… - …, 2021 - ncbi.nlm.nih.gov
Background: Several studies have revealed the potential use of tocilizumab in treating
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab …
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab …